Bioxyne (ASX:BXN) has announced that its wholly-owned subsidiary, Breathe Life Sciences, has manufactured and delivered Australia’s first pharmaceutical-grade cannabis pastilles under its Good Manufacturing Practice (GMP) certification from the TGA.
Bioxyne said Breathe Life Sciences has completed its first commercial production run of Australian-made cannabis pastilles, often called gummies. This follows the first commercial orders received in July.
Breathe Life Sciences has signed a two-year manufacturing and supply agreement with one of Australia’s largest cannabis companies. It is scaling up its manufacturing capabilities to meet growing demand from two million single doses to six million monthly.
Breathe Life Sciences founder and CEO and the managing director of Bioxyne, Sam Watson, said, “BLS is the first Australian manufacturer to complete a commercial production run of pharmaceutical grade GMP-certified THC gummies. As a leading Australian cannabis manufacturer, we are supplying our pharmaceutical goods to both domestic and international markets, using established relationships and existing supply channels.”